ADDvise receives allocation decision worth approximately 14.4 MSEK – Regulatory information

ADDvise Group AB’s (publ) subsidiary Hettich Labinstrument AB has received an allocation decision from Västra Götalandsregionen worth approximately 14.4 MSEK regarding blood sampling products. The period of the agreement is two years and starts in May 2019 with the possibility of an extension for a total of two years corresponding to an additional 14.4 MSEK.

The time for appeal has expired.  

For further information, please contact:

Rikard Akhtarzand, CEO.

+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

www.addvisegroup.se

Important information  

This information is required for ADDvise to disclose under the EU Market Abuse Regulation. The information was submitted for publication on March 8th 2019 at 13:10 CEST.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com

About Us

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier. Additional information is available at www.addvisegroup.com.

Subscribe

Documents & Links